Kornimate/medical-research-clean huggingface dataset:
aspirin/folate prevention of large bowel polyps

Conditions: Colorectal Cancer; Polyps; Adenomas

Summary: this is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.

this is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel among subjects with a recent history of these tumors. the study is a randomized, double-blind, placebo-controlled trial with a 2 x 3 factorial design.

Eligibility criteria:
inclusion criteria: 1. one neoplastic polyp removed within three months of study entry or within 16 months of study entry if over 1 cm in size or if subject has had a lifetime history of at least two polyps, with the entire large bowel seen by colonoscopy to be free of further polyps within 3 months of entry. 2. an ability and willingness to follow the study protocol, as indicated by the subject's giving informed consent to participate. 3. good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study. 4. anticipated colonoscopic follow-up three years after the qualifying colonoscopy. 5. age between 21 and 80 years at the time of the intake colonoscopy. 6. for women of childbearing potential, agreement to use effective birth control for the duration of the study. 7. intent not to take aspirin or aspirin-containing products, nsaids or folic acid for the length of the study unless required by a physician. 8. not randomized previously or currently in a chemoprevention trial, except for the: "nutritional prevention of large bowel polyps" study (polyps prevention study i); and brief participation in the "va cooperative study" with no continuing involvement. exclusion criteria: 1. invasive carcinoma in any colonic polyp removed. 2. familial colonic polyposis syndromes. 3. ulcerative colitis or crohn's disease. 4. malabsorption syndrome (e.g. pancreatic insufficiency). 5. large bowel resection for any reason. 6. diagnosed narcotic or alcohol dependence 7. contraindication to aspirin use, including: 1. documented peptic ulcer disease in the past 20 years 2. aspirin sensitivity 3. bleeding diathesis, including hemorrhagic stroke 8. likelihood of nsaid use 1. recurring arthritis or other musculo-skeletal problems 2. frequent nsaid use in 5 years preceding 3. history of stroke or tias 4. history of angina or myocardial infarction 5. desire to take aspirin for the prevention of cardiovascular disease 9. required or contraindicated folic acid use pernicious anemia or folic acid deficiency 10. pregnancy or lactation.

Keywords: colorectal neoplasms adenomatous polyps
mefloquine bioequivalence among 3 commercially available tablets.

Conditions: Malaria

Summary: the objective of this study was to determine the bioequivalence among three commercial tablet formulations of mq, i.e. lariam, mephaquin, and mefloquine-(ac farma) when given in combination with artesunate.

pharmacokinetic parameters were determined for mefloquine in whole blood from peruvian subjects with uncomplicated falciparum malaria administered mephaquin®, mefloquine-ac farma, and lariam®. the mefloquine-ac farma arm comprised 13 patients while the reference (lariam) and mephaquin arms consisted of 12 patients. although cmax was significantly less (p=0.04) in the mephaquin arm (auc0-t = 2500 ng/ml/day) relative to the reference (auc0-t = 2820 ng/ml/day) arm, there were no significant differences in the auc∞, tmax, and t1/2 for mefloquine-ac farma or mephaquin relative to the reference. except for the cmax of the mefloquine-ac farma, the 90% confidence intervals for all parameters of both treatments were outside the specified fda range of 80-125%. therefore both formulations were not considered bioequivalent to the reference.

Eligibility criteria:
inclusion criteria: * the inclusion criteria for enrolling patients included; male or non-pregnant female ≥ 18 years of age, infection with p. falciparum alone, with a parasite density between 250 and 50,000 asexual parasites/mm3 as determined by microscopic examination of a thick blood smear, informed consent from patient, and a willingness to be hospitalized for the first 24 hours after therapy is initiated and to return for follow-up visits through day 56. exclusion criteria: * patients exhibiting evidence of severe malaria or with a history of an underlying chronic disease or illness that could interfere with the absorption of mq, a history of hypersensitivity to mq, or a history of neuropsychiatric illness or cardiac conduction problems were excluded.

Keywords: mefloquine
visual rehabilitation after occipital stroke

Conditions: Stroke, Ischemic; Quadrantanopia; Vision Loss Partial; Visual Field Defect, Peripheral; Peripheral Visual Field Defect of Both Eyes; Peripheral Visual Field Defect; Hemianopsia; Hemianopia; Homonymous Hemianopia; Homonymous Hemianopsia; Visual Fields Hemianopsia; Occipital Lobe Infarct; Quadrantanopsia; Stroke Hemorrhagic

Summary: this research aims to examine changes in plastic potential of the visual system with time from stroke affecting primary visual cortex. we will measure structural and mechanistic aspects of progressive degeneration along the early visual pathways, correlating them with changes in visual performance, and in responsiveness to visual restoration training. this project will advance both scientific knowledge, as well as technical capability and clinical practices for restoring vision and quality of life for people suffering from cortical blindness.


Eligibility criteria:
inclusion criteria: * residents of us and canada * mri and/or ct scans showing evidence of one-sided / unilateral stroke or stroke-like damage to the primary visual cortex or its immediate afferent white matter sustained less than 6-months prior to enrollment * reliable visual field defects in both eyes as measured by humphrey, macular integrity assessment (maia), goldmann, and/or equivalent perimetry. this deficit must be large enough to enclose a 5-deg diameter visual stimulus. * ability to fixate on visual targets reliably for 1000ms (as demonstrated by visual fields, and verified in study participation) * willing and safely able to undergo magnetic resonance imaging (mri) scanning * willing, able, and competent to provide informed consent * fluent in written and spoken english * cognitively able, responsible, and willing to complete daily visual training independently at home for several months. exclusion criteria: * past or present ocular disease interfering with vision * best corrected visual acuity worse than 20/40 in either eye * presence of damage to the dorsal lateral geniculate nucleus, as shown on mri/ct scans * diffuse, whole brain degenerative processes * brain damage deemed by study staff to potentially interfere with training ability or outcome measures * history of traumatic brain injury * documented history of drug/alcohol abuse * currently use of neuroactive medications which would impact training, as determined by pi * cognitive or seizure disorders * one-sided attentional neglect * inability to perform the visual training exercises as directed

Keywords: occipital stroke vision loss homonymous quadrantanopia homonymous quadrantanopsia stroke vision loss after stroke vision recovery vision restoration partial vision loss
effect of changing diet on fasting and post fat load lipoproteins

Conditions: Hypertriglyceridemia; Diabetes Mellitus

Summary: the study examines the effect of two diets on fasting and post fat load lipoproteins of subjects with type 2 diabetes with moderate hypertriglyceridemia.


Eligibility criteria:
inclusion criteria: * male and female, * 18 - 75 years of age * type 2 diabetes * fasting triglycerides 300 -800mg/dl
to compare lidocaine2%/clonidine in combination, with bupivacaine 0.5 % alone in equal volumes for combined sciatic-saphenous nerve block in terms of selectivity of blockade

Conditions: Bimalleolar Fractures of the Ankle.; Sciatic Nerve Block.; Saphenous Nerve Block.; Post Operative Analgesia Duration.

Summary: clonidine as an adjuvant to local anaesthetics prolongs the postoperative analgesia. it is predominantly an alpha 2 agonist, but does have some alpha 1 activity. clonidine alone produces analgesia. when administered centrally its effects are predominantly due to its alpha 2 activity. when administered peripherally it prolongs the analgesia through its vasoconstrictor effects and by reducing the clearance of local anaesthetic. another possibility is that it prolongs analgesia of peripheral nerve blocks due to a hyperpolarisation current .clonidine has been used successfully both for upper and lower limb blocks. studies of clonidine for lower limb blocks have produced equivocal results . a major concern with the lower limb blocks is the risk of falls associated with prolonged motor blockade during early mobilisation. clonidine has been shown to intensify and prolong the motor blockade produced by long acting local anaesthetics. lidocaine when used in combination with clonidine can increase the duration of analgesia to 8-18 hrs. greater doses of clonidine are associated with longer analgesia but with more side effects. clonidine in a dose of 90 mcg administered with local anaesthetics can produce analgesia for up to 10 hrs with minimal side effects. the aim of this study is to compare lidocaine 2% + clonidine 1.5mcg/kg with bupivacaine alone in terms of block selectivity for combined sciatic -saphenous nerve block in patients under going semi elective foot/ankle procedures.


Eligibility criteria:
inclusion criteria: * asa 1-3 patients scheduled to undergo semi elective ankle/foot surgery with regional anaesthesia will be recruited. exclusion criteria: * patient refusal, * allergy to local anaesthetics, * coagulopathy, * malignancy or infection at the block performance site, * significant peripheral neuropathy or neurologic disorder of the lower extremity or any other contraindication to sciatic and saphenous nerve block, * pregnancy, * history of alcohol or drug dependency/abuse (defined as \>40 iu/week), * a history of significant cognitive or psychiatric disorder that may affect patient assessment.

Keywords: local anaesthesia analgesia bupivacaine lidocaine clonidine sciatic nerve saphenous nerve
open-label study of asp2151 in herpes simplex patients

Conditions: Herpes Simplex

Summary: a multicenter, open-label study is conducted to evaluate the efficacy and safety of asp2151 in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes and kaposi varicelliform).


Eligibility criteria:
inclusion criteria: 1. patients with a rash associated with herpes simplex and a recurrent episode meeting the following criteria * recurrent labial/facial herpes: patients with at least 10 papulae or vesicles/pustules * recurrent genital herpes: patients with at least 5 papules or vesicles/pustules on the genital organs or in the genital and circumanal region * kaposi varicelliform eruption: patients with major skin symptoms of papulae or vesicles 2. patients who can start receiving the study drug within 48 hours after onset of rash 3. age: 16 years or older, but younger than 80 years exclusion criteria: 1. patients who are not expected to have an adequate response to oral antiviral medication. 2. patients with two or more types of herpes simplex. 3. an extreme decline in immune function 4. presence of serious complications 5. patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent: * ast or alt ≥ 2.5 x upper limit of normal * platelet count \< lower limit of normal * serum creatinine ≥ 1.5 mg/dl * creatinine clearance \< 30 ml/min 6. current or previous history of malignant tumor within 5 years before informed consent 7. diagnosis of autoimmune disease
bdnf levels in cancer patients receiving chemotherapy

Conditions: BDNF; Cognitive Functions; Chemotherapy

Summary: cognitive impairment following chemotherapy is defined as chemotherapy-induced cognitive impairment (cciid). cciid, which significantly reduces the quality of life of cancer patients receiving chemotherapy, develops as a result of neurotoxicity. it is stated that 75% of patients receiving chemotherapy have cognitive changes. in addition, 35% of patients complain of various cognitive impairments (hearing, perception, decision-making, etc.) for a few months after chemotherapy ends. this situation makes life conditions very difficult for patients who are already experiencing a very difficult disease and treatment process. brain-derived neurotrophic factor (bdnf) is an extracellular signaling protein known for its dominant role in the development of the nervous system, such as neurogenesis, neuroprotection, neurodegeneration, synaptic plasticity, and resistance to neuronal stress. this protein has opposing effects with its mature form, pro-bdnf protein, and pro-bdnf/bdnf ratios affect neuronal health. although a number of factors have been identified that are responsible for the deterioration of the cognitive levels of patients receiving chemotherapy, the role of bdnf and pro-bdnf levels in cognitive functions in cancer patients receiving chemotherapy is unknown. in light of this information, the aim of our study is to reveal the effects of chemotherapy-induced cognitive impairment (ciid) on pro-bdnf/bdnf levels and to evaluate the cognitive effects. in line with this aim, patients who apply to çanakkale onsekiz mart university, faculty of medicine, department of oncology, polyclinic and chemotherapy unit and who have not yet received their first chemotherapy will be included in the study. before the first chemotherapy, during routine follow-ups in the 3rd month of chemotherapy and in the 6th month in aydın, 1 extra tube of blood will be taken and bdnf levels will be examined. at the same time, the montreal cognitive assessment (moca) test will be applied to the patients to evaluate their cognitive functions. thus, serum bndf, probdnf levels will be determined and the bdnf/probdnf ratio will be revealed.

detection of chemotherapy-induced cognitive impairment

Eligibility criteria:
inclusion criteria: * cancer definations and decided the chemotherapy treatment exclusion criteria: * having other disease whixh effected cognitive function * brain cancers * brain metastasis
epidermal growth factor receptor and k-ras mutations in patients with stage iii non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage iii non-small cell lung cancer.

objectives: * determine the frequency of epidermal growth factor receptor (egfr) and k-ras mutations in patients with stage iii non-small cell lung cancer (nsclc) treated on calgb 30106. * correlate presence or absence of egfr and/or k-ras mutations with radiographic response to treatment in these patients. outline: tissue samples are analyzed for epidermal growth factor receptor and k-ras mutations.

Eligibility criteria:
inclusion criteria: 1. eligible patients had histologic documentation of un- treated stage iii nsclc. 2. radiation oncologist confirmation was required that radiation could be given per protocol. 3. eastern cooperative group criteria performance status of 0 to 2 4. tumor specimen paraffin block or unstained slides and standard initial laboratory tests 5. signed institutional review board-approved, protocol-specific in- formed consent in accordance with federal and institutional guidelines exclusion criteria: 1. patients with scalene, supraclavicular, or contralateral hilar lymph node involvement, or direct invasion of the vertebral body or with a pleural effusion were ineligible.

Keywords: stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer
efficacy of epoetin alfa deep tank in treatment of anemia in patients with chronic kidney disease receiving hemodialysis

Conditions: Nephrology

Summary: the purpose of this study is to evaluate whether the efficacy of epoetin alfa dt is equivalent to that of epoetin alfa rb for the treatment of anemia in patients with ckd receiving hemodialysis


Eligibility criteria:
inclusion criteria: - diagnosis of ckd and receiving hemodialysis for greater than or equal to 3 months before randomization - mean hb level between 10 and 13 g/dl (inclusive) (mean of 2 values drawn at least 3 days apart during the screening period) - currently receiving a stable dose of epoetin alfa rb (i.e., epogen® or procrit®) for at least 6 weeks prior to randomization. stable is defined as: less than or equal to 25% change in dose over 6 weeks, same frequency and route of administration with no more than 1 missed or withheld dose during each of the two three-week periods before randomization exclusion criteria: - uncontrolled hypertension, defined as a pre-dialysis systolic bp greater than 180 and/or diastolic bp of greater than 110 during the screening period - known history of severe hyperparathyroidism (pth greater than 1500 pg/ml within 3 months prior to enrollment) - currently receiving immunosuppressive therapy

Keywords: anemia chronic kidney disease, ckd hemodialysis epoetin epogen®
inhaled salbutamol vs placebo for the treatment of acute ige-mediated abdominal pain from allergic food reactions

Conditions: IgE-mediated Abdominal Pain

Summary: the goal of this study is to assess the efficacy of inhaled salbutamol to treat abdominal pain during food allergic reactions. patients experiencing abominal pain as a result of a food allergic reaction during a food challenge in the allergy clinic will be invited to participate to the study. they will receive either 8 puffs of salbutamol (asthma inhaler) or 8 puffs of a placebo inhaler. the abdominal pain will then be followed using a numeric scale to see if patients receiving the medication experienced a faster improvement compared to those receiving the placebo.

this trial aims to compare the efficacy of inhaled salbutamol compared to placebo to decrease the duration of abdominal pain in children and adults with ige-mediated food allergic reactions. the population will be children and adults aged 6 to 55 presenting with moderate to severe ige-mediated abdominal pain in the context of an oral food challenge or an oral immunotherapy dose increase at the allergy clinic. eligible participants will be randomized to receive an immediate treatement with either inhaled salbutamol 800 mcg or inhaled placebo, dispensed with a spacer, at a ratio of 1:1. participants will be asked to rate the evolution of their abdominal pain by the minute on the nrs-11 scale until it resolves completely or that they have been discharged. patients still presenting moderate to severe abdominal pain 30 minutes after the administration of the investigational product will receive an open-label treatment with 800 mcg of inhaled salbutamol. the primary outcome is the time from treatment to a decrease of the abdominal pain down to a mild intensity (defined as a pain for which the patient would not normally seek treatment). participants will be contacted by phone after three days to document any adverse event. the primary endpoint will be analysed using a log-rank test.

Eligibility criteria:
inclusion criteria: * subjects aged between 6 to 55 years old. * undergoing an oral food challenge or an oral immunotherapy up-dosing visit for the diagnosis or treatment of an ige-mediated food allergy. * previous confirmation of the food allergy by either skin prick tests (spt) or serum specific ige; * able to express the intensity of their pain using the nrs-11; * willing to comply with all study requirements. exclusion criteria: * previous adverse reactions to salbutamol; * known hypersensitivity to salbutamol or placebo or any of their components; * any condition that could be considered a relative contra-indication to the use of salbutamol according to the investigator (e.g. patient with a history of hyperglycemia, arrhythmia or hypokalemia); * patients receiving beta-blockers or a daily / long-acting beta agonists; * patients needing to pass an anti-doping test for high-level sport in the following 24h.

Keywords: food allergy anaphylaxis
investigating the use of goal management therapy in improving cognitive functioning in public safety personnel with ptsd

Conditions: Post Traumatic Stress Disorder; Cognitive Deficit

Summary: this study examines the efficacy of goal management therapy (gmt) - a well-established cognitive remediation strategy aimed at improving goal-directed behaviors that are dependent on basic cognitive processes and on executive functioning - among public safety personnel with post-traumatic stress disorder.

goal management therapy is a structured, short-term, cbt-based, cognitive remediation program with an emphasis on mindfulness, and practice in planning and completion of goal-oriented behaviours. the primary objective of gmt is to train participants to interrupt ongoing, disruptive behaviour through the resumption of executive control, in order to define goal hierarchies and monitor performance in achieving goals. sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities. the matched psychosocial education control group will focus on educating participants on topics like brain function and neuroplasticity, and on practicing lifestyle interventions (e.g., sleep hygiene, stress management, exercise). the study will take place in three phases: phase 1 will consist of 6 sessions of goal management therapy and 6 sessions of psychosocial education among public safety personnel and civilians who are inpatients at a mental health and addiction facility. phase 2 will consist of 9 sessions of goal management therapy and 9 sessions of psychosocial education among public safety personnel who are members of the local community. phase 3 will consist of 9 sessions of goal management therapy and 9 sessions of psychosocial education among public safety personnel who are members of the local community. this phase will also use functional magnetic resonance imaging (fmri) scans to investigate potential changes in the neurobiology of participants' brains.

Eligibility criteria:
inclusion criteria: * have a diagnosis of post-traumatic stress disorder on the clinician administered ptsd scale (caps) * are able to provide written informed consent exclusion criteria: * receiving treatment with anti-cholinergics, anti-psychotic medication, or psychostimulants * use of benzodiazepines within the last 24 hours * have had electroconvulsive therapy within the past year * a diagnosis of substance dependence or abuse within the past 6 months * a recent history (within the past 12 months) of medical disorder known to adversely affect cognition * a history of head trauma with more than one minute of loss of consciousness or a history of traumatic brain injury * a history of neurological disorder * a diagnosis of psychotic disorder or bipolar disorder * a history of a neurodevelopmental disorder

Keywords: cognitive remediation public safety personnel psychosocial education first responders military
dextrose, steroid, prp: choosing the right injection for crs relief; a rct

Conditions: Carpal Tunnel Syndrome

Summary: usg guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or prp


Eligibility criteria:
inclusion criteria: * na exclusion criteria: * na